DEST Insider Trading (Destiny Pharma plc (DEST.L))

Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing XF-73 Nasal that is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal, which is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops XF-70 for ventilator associated pneumonia/cystic fibrosis/bronchiectasis; DPD-207 for eye infections caused by bacteria and fungi; and XF drugs for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. The company has a collaboration agreement with China Medical System Holdings Limited; research collaboration with the University of Southampton for targeting infections in diabetic foot ulcers and cystic fibrosis; research collaboration with the University of Sheffield; research collaboration with Aston University to investigate novel antimicrobial candidates from its XF-drug platform; collaboration with Cardiff University and Tianjin Medical University; and Collaboration with SporeGen Limited to co-develop treatment for COVID-19. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.